Non-Hodgkin's lymphoma unspecified histology aggressive recurrent

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (rat) 1 substance
Phase III: 1 Phase I: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2022-502783-21-00 10 countries 2024 n=132 Orphan
    Recruiting

Phase I

1 trial
  • Regeneron Pharmaceuticals Inc. Academic
    IMP not specified
    2022-502137-26-00 3 countries 2024 n=42
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Regeneron Pharmaceuticals Inc. Commercial 2 Phase III, Phase I 1
New trials by year
2024
2
← All indication landscapes